Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Mycophenolate Mofetil

Aliases
Cellcept, Cellcept®, CellCept, CellCept®, CELLCEPT (3 other aliases)
Name
CellCept
FDA Approved
Yes

63 clinical trials

2 organizations

131 indications

1 document

Indication
Kidney Transplant
Indication
Neuromyelitis Optica Spectrum Disorder
Indication
Lupus Nephritis
Indication
Acute Lymphoblastic Leukemia
Indication
Myelodysplastic Syndromes
Indication
T-lymphoblastic lymphoma
Indication
Acute Lymphocytic Leukemia
Indication
Acute Myeloid Leukemia
Indication
Acute Biphenotypic Leukemia
Indication
Acute Undifferentiated Leukemia
Indication
Kidney Transplantation
Indication
Vogt-Koyanagi-Harada Syndrome
Indication
Mycophenolate Mofetil
Indication
Leukemia
Indication
lymphoma
Indication
Primary Immune Deficiency Disorder
Indication
Primary Immunodeficiency Disease
Indication
Bone Marrow Failure
Indication
Primary Myelofibrosis
Indication
Graft-Versus-Host Disease
Indication
Hematologic Neoplasms
Indication
Non-infectious Uveitis
Indication
Hematopoietic and Lymphoid System Neoplasm
Indication
Heart Transplant
Indication
Acute Lymphoblastic
Indication
Myeloid Leukemia
Indication
Acute
Indication
Biphenotypic Acute Leukemia
Indication
Lymphoblastic Lymphoma
Indication
Myeloproliferative Neoplasm
Indication
Myelodysplastic Syndrome
Indication
Hematologic Malignancies
Indication
Chronic Myelomonocytic Leukemia
Indication
Hematologic Disorders
Indication
Leukemia, Myeloid, Acute
Indication
Chronic Myelogenous Leukemia
Indication
Accelerated Phase
Indication
Blastic Phase
Indication
mantle cell lymphoma
Indication
Follicular Lymphoma
Indication
Diffuse Large B-Cell Lymphoma
Indication
Non-Hodgkin Lymphoma
Indication
Graft-Vs-Host Disease
Indication
Graft-versus-host disease
Indication
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Indication
Recurrent Acute Myeloid Leukemia
Indication
Recurrent Mixed Phenotype Acute Leukemia
Indication
Mixed Phenotype Acute Leukemia
Indication
Small Cell Lung Cancer
Indication
Small Cell Lung Carcinoma
Indication
Immune Thrombocytopenia Purpura
Indication
GATA-2 deficiency
Indication
Immunodeficiency
Indication
Multiple Myeloma
Indication
Chronic Myeloid Leukemia
Indication
Chronic Lymphocytic Leukemia
Indication
Prolymphocytic Leukemia
Indication
Myelofibrosis
Indication
Systemic Lupus Erythematosus
Indication
Graves' Disease
Indication
Stem Cell Transplant Complications
Indication
Nephrotic Syndrome in Children
Indication
Recurrent chronic myelomonocytic leukemia
Indication
Myelodysplastic-Myeloproliferative Diseases
Indication
Myeloproliferative Disorder
Indication
Hodgkin lymphoma
Indication
Refractory Acute Leukemia of Ambiguous Lineage
Indication
Refractory Acute Undifferentiated Leukemia
Indication
Adult Acute Lymphoblastic Leukemia
Indication
Adult Acute Myeloid Leukemia
Indication
Recurrent Hematologic Malignancy
Indication
Non-Hodgkin's Lymphoma
Indication
Hodgkin's disease
Indication
Peripheral T-cell Lymphoma
Indication
Scleroderma
Indication
Systemic
Indication
Interstitial Lung Disease
Indication
Childhood Acute Lymphoblastic Leukemia
Indication
Aggressive Non-Hodgkin Lymphoma
Indication
Myelodysplastic/Myeloproliferative Neoplasm
Indication
Systemic Sclerosis
Indication
BCR-ABL1-positive
Indication
Recurrent Aggressive Non-Hodgkin Lymphoma
Indication
Recurrent B-Cell Non-Hodgkin Lymphoma
Indication
Burkitt Lymphoma
Indication
Recurrent Diffuse Large B-Cell Lymphoma
Indication
Recurrent High Grade B-Cell Lymphoma
Indication
Recurrent T-Cell Non-Hodgkin Lymphoma
Indication
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Indication
Immunosuppression
Indication
Chronic Myelogenous Leukemia (CML)
Indication
acute myeloid leukemia
Indication
Acute lymphoblastic leukemia
Indication
MDS
Indication
MPD Without Myelofibrosis
Indication
Non-Hodgkin lymphoma
Indication
Inherited Metabolic Disorders
Indication
Hemoglobinopathies
Indication
Hemophagocytic lymphohistiocytosis
Indication
Pediatric Heart Transplantation
Indication
Immune suppression
Indication
Chronic Kidney Disease
Indication
Cardiac Allograft Vasculopathy
Indication
Heart Transplant Rejection
Indication
Post-transplant Lymphoproliferative Disorder
Indication
Heart Transplant Infection
Indication
Aplastic Anemia
Indication
Acquired Amegakaryocytic Thrombocytopenia
Indication
Acquired Pure Red Cell Aplasia
Indication
Paroxysmal Nocturnal Hemoglobinuria
Indication
Autoimmune Diseases
Indication
Systemic Sclerosis With Lung Involvement
Indication
systemic sclerosis
Indication
Plasma Cell Leukemia
Indication
myeloid
Indication
Myelodysplastic Syndrome With Excess Blasts-1
Indication
Burkitt lymphoma
Indication
Relapsed T-Cell Lymphoma
Indication
Small Lymphocytic Lymphoma
Indication
Marginal Zone Lymphoma
Indication
Biphenotypic/Undifferentiated Leukemia
Indication
Relapsed large B-cell lymphoma
Indication
Waldenstrom Macroglobulinemia
Indication
Cytomegalovirus Infections
Indication
Inflammatory Cardiomyopathy
Indication
Lung Transplant Complications
Indication
Essential Thrombocythemia
Indication
Hematopoietic and Lymphoid Cell Neoplasm
Indication
Myeloid Neoplasm
Indication
Polycythemia Vera
Indication
End-Stage Renal Disease
Clinical trial
A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
Status: Completed, Estimated PCD: 2014-06-30
Clinical trial
A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Status: Active (not recruiting), Estimated PCD: 2024-05-25
Clinical trial
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients
Status: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
Status: Terminated, Estimated PCD: 2020-10-29
Clinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
An Observational Study of Mycophenolate Mofetil Combined With Glucocorticoid in the Treatment of Relapse Vogt-Koyanagi-Harada Disease
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Status: Active (not recruiting), Estimated PCD: 2009-11-11
Clinical trial
Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study
Status: Active (not recruiting), Estimated PCD: 2022-12-28
Clinical trial
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Randomized Controlled Multicenter Study Comparing Efficacy and Safety of Adalimumab to That of Mycophenolate Mofetil in Steroid Dependent Non-infectious Uveitis
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)
Status: , Estimated PCD: 2023-01-13
Clinical trial
Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Belatacept in De Novo Heart Transplantation - Pilot Study
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Status: Completed, Estimated PCD: 2024-04-30
Clinical trial
Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia
Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
Reduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies Using Donors Other Than First-degree Relatives
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase-I/II Trial to Assess the Safety and Efficacy of Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (FLAMSAClax
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
An Outcome Study of Conventional Steroids vs. Steroids Combined With Mycophenolate for the Management of Newly Diagnosed Immune Thrombocytopenia Purpura: A Cost Effective Measure in Developing Nations.
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
Status: Recruiting, Estimated PCD: 2031-07-31
Clinical trial
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study
Status: Terminated, Estimated PCD: 2021-05-08
Clinical trial
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
The Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial
Status: Recruiting, Estimated PCD: 2025-10-08
Clinical trial
A Randomized, Multicenter, Open-label Phase II Trial to Compare Prophylaxis of Graft Versus Host Disease With Tacrolimus and Mycophenolate Mofetil Versus Ruxolitinib After Post-transplant Cyclophosphamide
Status: Active (not recruiting), Estimated PCD: 2023-02-27
Clinical trial
Rituximab Versus Mycophenolate Mofetil in Children With Steriod-dependent Nephrotic Syndrome: A Single-center, Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled Trial of Mycophenolate Mofetil Alone or With Voclosporin for Systemic Lupus: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment (DIVERT) (ALE10)
Status: Recruiting, Estimated PCD: 2025-06-20
Clinical trial
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis
Status: Recruiting, Estimated PCD: 2025-03-24
Clinical trial
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
Status: Active (not recruiting), Estimated PCD: 2025-02-07
Clinical trial
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation
Status: Completed, Estimated PCD: 2008-12-30
Clinical trial
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Status: Completed, Estimated PCD: 2022-03-23
Clinical trial
Efficacy & Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis- A Double-Blind Placebo Controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-10-11
Clinical trial
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Vorinostat With Gemcitabine/Clofarabine/Busulfan for Allogeneic Transplantation for Aggressive Lymphomas
Status: Withdrawn, Estimated PCD: 2021-10-29
Clinical trial
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Status: Recruiting, Estimated PCD: 2035-05-01
Clinical trial
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Status: Completed, Estimated PCD: 2022-09-19
Clinical trial
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
Status: Recruiting, Estimated PCD: 2025-12-20
Clinical trial
Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation
Status: Active (not recruiting), Estimated PCD: 2023-04-17
Clinical trial
Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: a Randomized, Multicenter, Open-label, Parallel-arm Study
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
Efficacy of Mycophenolate Mofetil Versus Leflunomide as Maintenance Treatment for IgG4-RD Patients With Internal Organ Involvement
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Randomized Double-Blind Placebo-Controlled Clinical Trial to Assess the Efficacy of Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated With Systemic Sclerosis: a Feasibility Study
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2027-10-22
Clinical trial
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status: Active (not recruiting), Estimated PCD: 2020-06-23
Clinical trial
Effect of the Introduction of mTor Inhibitors in the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response to Control Viral Replication in Kidney Transplant Patients
Status: Withdrawn, Estimated PCD: 2021-09-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled TRial Evaluating Immunosuppressive Treatment in Patients With Chronic Virus-Negative Inflammatory cardiomyopaThY (TRINITY Trial)
Status: Recruiting, Estimated PCD: 2027-03-28
Clinical trial
A Randomised Prospective Open Label Pilot Trial Comparing Mycophenolate Mofetil (MMF) With no Immunosuppression in Adults With Limited Cutaneous Systemic Sclerosis
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus (Envarsus XR) in Lung Transplant Recipients
Status: , Estimated PCD: 2026-06-30
Clinical trial
A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Head to Head Comparison of Myfortic vs. Cellcept in the Treatment of Kidney Transplant Recipients Using Our Current Center Standardized Concomitant Immunosuppressive Protocol
Status: Completed
Document
DailyMed Label: CellCept
Organization
Rebel Distributors Corp.
Organization
Genentech, Inc.